Circulogene Funding: How Much Did They Raise & Key Investors

How Much Did Circulogene Raise?
Funding & Key Investors

Circulogene, a specialist in liquid biopsy and genomic testing for solid tumors, has secured $2.3M in total capital. The company recently announced a $350K strategic investment, underscoring its pivotal role in advancing precision oncology. This latest financing round signifies a critical juncture for Circulogene as it aims to expand its capabilities in personalized cancer treatment and monitoring.

The company's innovative offerings, including LungLifeAI for pulmonary nodule assessment and OncoGenDx for precision oncology decisions, are designed to enhance patient outcomes through advanced molecular and genomic profiling. With a history of supporting over 25,000 cancer patients, Circulogene leverages next-generation sequencing and PCR technology to improve the detection and monitoring of cancer-associated genes.

What is Circulogene?

Circulogene

Healthcare Services

Medical Laboratories & Imaging Centers

Circulogene operates at the forefront of liquid biopsy technology, providing comprehensive genomic profiling for solid tumors across all stages of cancer. Their suite of advanced molecular and genomic tests is engineered to support personalized treatment strategies and improve patient survival rates. By integrating cutting-edge next-generation sequencing and PCR technologies, Circulogene enhances the accuracy and efficiency of cancer gene detection and monitoring, positioning itself as a key player in the diagnostic and precision medicine landscape.

How much funding has Circulogene raised?

Circulogene has raised a total of $2.3M across 3 funding rounds:

2015

Private Equity

$1.2M

2016

Debt

$750K

2020

Debt

$350K

Private Equity (2015): $1.2M, investors not publicly disclosed

Debt (2016): $750K, investors not publicly disclosed

Debt (2020): $350K supported by PPP

Key Investors in Circulogene

PPP

Public-Private Partnership

What's next for Circulogene?

The recent strategic investment of $350K signals Circulogene's transition into a scaling phase, likely focused on expanding its market reach and further developing its proprietary testing platforms. This infusion of capital is expected to accelerate the adoption of its innovative solutions, such as LungLifeAI and OncoGenDx, within the oncology community. Future growth may involve strategic partnerships with healthcare providers and pharmaceutical companies to integrate Circulogene's genomic insights into broader clinical workflows and drug development pipelines, solidifying its position in the competitive liquid biopsy market.

See full Circulogene company page

See More Financial Insights